Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 78.25
Day High 79.27
Open:78.36
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
BusinessWire - 15 minutes ago
BusinessWire - CMTX
15 minutes ago
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2a (HIF-2a) for the treatment of patients with cancer and other non-oncology diseases. Peloton's lead candidate is PT2977, a novel oral HIF-2a inhibitor in late-stage development for renal cell carcinoma (RCC).
Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA(R) (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
BusinessWire - Mon May 20, 3:30PM CDT
BusinessWire - CMTX
Mon May 20, 3:30PM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer (TNBC) did not meet its pre-specified primary endpoint of superior overall survival (OS) compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine). Other endpoints were not formally tested per the study protocol because the primary endpoint of OS was not met. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies involving patients treated with KEYTRUDA monotherapy; no new safety concerns were identified. Results will be presented at an upcoming medical meeting.
At 9.3 % CAGR, Basal Cell Carcinoma Treatment Market Size will reach 7700 million US$ in 2023
Heraldkeeper - Mon May 20, 10:16AM CDT
Heraldkeeper - CMTX
Mon May 20, 10:16AM CDT
The latest research at Market Study Report on Basal Cell Carcinoma Treatment Market provides a comprehensive analysis of the Basal Cell Carcinoma Treatment market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities of global industry. This report also provides market landscape and market share information in the Basal Cell Carcinoma Treatment industry.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 72.74 +8.44% increase
on 04/22/19
Period Open:73.19
Price movement based on the high, low and last over the given period.
80.14 -1.58% decrease
on 05/03/19
+5.69 (+7.77%) increase
since 04/18/19
3-Month 72.23 +9.21% increase
on 04/18/19
Period Open:79.43
Price movement based on the high, low and last over the given period.
83.85 -5.93% decrease
on 04/01/19
-0.55 (-0.69%) decrease
since 02/20/19
52-Week 58.03 +35.94% increase
on 05/29/18
Period Open:59.14
Price movement based on the high, low and last over the given period.
83.85 -5.93% decrease
on 04/01/19
+19.74 (+33.38%) increase
since 05/18/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).